Trained with 1M+ cell annotations by 150+ pathologists worldwide, Lunit SCOPE PD-L1 generates analysis results that are close to the ground truth.
By generating objective results, Lunit SCOPE PD-L1 reduces interpretation discrepancy between pathologists.
Based on an accuracy of 96%, Lunit SCOPE PD-L1 finds 50% more patients eligible for immunotherapy compared to human-classified PD-L1(-) patient group.
Detects tumor cell PD-L1 +/- and inflammatory cell PD-L1 +/- from whole slide images
Calculates PD-L1 positive score including TPS (Tumor Proportion Score) and CPS (Combined Positive Score; to be provided).
Provides AI analysis results including PD-L1 TPS score and map within a report.
*User-read is computed by user defined PD-L1 positive and negative cells within user drawn ROI.
How it works